This FAME 3 substudy aimed to define the value of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) and intravascular imaging for cardiovascular failure. In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the substudy of the FAME 3 trial and the implications for clinical practice.
The abstract entitled ‘FAME 3 Substudies: Clinical Outcomes Related to Anatomic vs Functional Significance and Prognostic Value of Post-PCI FFR II’ was presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, 16 – 19, September 2022.
Questions:
- What were the aims and design of the study you are presenting? (0:18)
- What factors were found to be independent predictors of target vessel failure? (2:11)
- How did the use of intravascular imaging affect outcomes? (4:04)
- What will be the impact of these findings on clinical practice? (5:06)
Disclosures: Zsolt Piroth is on the advisory board for Abbott and the speaker’s bureau and a consultant for Abbott, Boston Scientific and OpSens.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of TCT 2022
Access more content on Interventional Cardiology here and Cardiovascular Disease here
